Advertisement

LDL Cholesterol and Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation

Published:September 28, 2020DOI:https://doi.org/10.1016/j.amjmed.2020.08.035

      Abstract

      Background

      Atrial fibrillation confers higher risk of ischemic stroke, but the contribution of low-density lipoprotein cholesterol (LDL-C) levels to this risk remains unclear. We examined the association between LDL-C levels and incident stroke in patients with atrial fibrillation treated with direct oral anticoagulants (DOACs).

      Methods

      This study was conducted using the electronic database of Clalit Health Services in Israel. Included were 21,229 patients with first-time diagnosis of nonvalvular atrial fibrillation treated with DOACs between 2010 and 2017. Patients were categorized into 4 groups according to the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years [doubled], type 2 diabetes, previous stroke or transient ischemic attack [doubled], vascular disease, age 65-74 years, and sex category) score (1-2, 3-4, 5-6, 7-9). Each group was further stratified to 4 sub-groups according to LDL-C levels (<70, 70-99, 100-130, >130 mg/dL). Ischemic stroke rates were compared among the 4 LDL-C subgroups of each CHA2DS2-VASc category.

      Results

      During 56,467 person-years of follow-up, there were 2481 incidents of ischemic stroke. Higher CHA2DS2-VASc score was associated with significantly increased risk of ischemic stroke (17.5, 26.9, 46.3, 94.9 cases per 1000 person-years, for patients with CHA2DS2-VASc score of 1-2, 3-4, 5-6, and 7-9, respectively; P < .001). However, there was no association between LDL-C levels and incident ischemic stroke within each CHA2DS2-VASc score group, even following a multivariate adjustment. Subanalyses of patients with previous stroke and those treated with statins also failed to show any association between LDL-C levels and incident ischemic stroke.

      Conclusions

      Unlike the general population, LDL-C levels were not associated with ischemic stroke risk among patients with atrial fibrillation treated with DOACs. The findings support the noninclusion of dyslipidemia in ischemic stroke risk stratification of patients with atrial fibrillation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Peters SA
        • Singhateh Y
        • Mackay D
        • Huxley RR
        • Woodward M
        Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis.
        Atherosclerosis. 2016; 248: 123-131
        • Hindy G
        • Engström G
        • Larsson SC
        • et al.
        Role of blood lipids in the development of ischemic stroke and its subtypes: a Mendelian randomization study.
        Stroke. 2018; 49: 820-827
        • Berger JS
        • McGinn AP
        • Howard BV
        • et al.
        Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women.
        Stroke. 2012; 43: 958-966
        • Amarenco P
        • Kim JS
        • Labreuche J
        • et al.
        A comparison of two LDL cholesterol targets after ischemic stroke.
        N Engl J Med. 2020; 382: 9
        • De Caterina R
        • Salvatore T
        • Marchioli R
        Cholesterol-lowering interventions and stroke: insights from IMPROVE-IT.
        Atherosclerosis. 2016; 248: 216-218
        • Du H
        • Li X
        • Su N
        • et al.
        Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
        Heart. 2019; 105: 1149-1159
        • Meschia JF
        • Bushnell C
        • Boden-Albala B
        • et al.
        Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2014; 45: 3754-3832
        • Mach F
        • Baigent C
        • Catapano AL
        • et al.
        2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
        Eur Heart J. 2020; 41: 111-188
        • Qi Z
        • Chen H
        • Wen Z
        • et al.
        Relation of low-density lipoprotein cholesterol to ischemic stroke in patients with nonvalvular atrial fibrillation.
        Am J Cardiol. 2017; 119: 1224-1228
        • Yang PS
        • Pak HN
        • Park DH
        • et al.
        Non-cardioembolic risk factors in atrial fibrillation-associated ischemic stroke.
        PLoS One. 2018; 13e0201062
        • Kim YD
        • Cha MJ
        • Kim J
        • et al.
        Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation.
        Stroke. 2011; 42: 930-934
        • Kim SJ
        • Ryoo S
        • Kwon S
        • et al.
        Is atrial fibrillation always a culprit of stroke in patients with atrial fibrillation plus stroke?.
        Cerebrovasc Dis. 2013; 36: 373-382
        • Hart RG
        • Pearce LA
        • Miller VT
        • et al.
        Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies.
        Cerebrovasc Dis. 2000; 10: 39-43
        • Katsi V
        • Georgiopoulos G
        • Skafida A
        • et al.
        Noncardioembolic stroke in patients with atrial fibrillation.
        Angiology. 2019; 70: 299-304
        • Benbir G
        • Uluduz D
        • Ince B
        • Bozluolcay M
        Atherothrombotic ischemic stroke in patients with atrial fibrillation.
        Clin Neurol Neurosurg. 2007; 109: 485-490
        • Eikelboom JW
        • Connolly SJ
        • Bosch J
        • et al.
        Rivaroxaban with or without aspirin in stable cardiovascular disease.
        N Engl J Med. 2017; 377: 1319-1330
        • Perera KS
        • Ng KKH
        • Nayar S
        • et al.
        Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS Trial.
        JAMA Neurol. 2020; 77: 43-48
        • Anand SS
        • Bosch J
        • Eikelboom JW
        • et al.
        Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
        Lancet. 2018; 391: 219-229